A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Study To Evaluate The Efficacy And Safety Of Pf-04965842 Monotherapy In Subjects Aged 12 Years And Older, With Moderate To Severe Atopic Dermatitis

Trial Profile

A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Study To Evaluate The Efficacy And Safety Of Pf-04965842 Monotherapy In Subjects Aged 12 Years And Older, With Moderate To Severe Atopic Dermatitis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Aug 2018

At a glance

  • Drugs PF 4965842 (Primary)
  • Indications Atopic dermatitis
  • Focus Registrational; Therapeutic Use
  • Acronyms JADE Mono-1
  • Sponsors Pfizer
  • Most Recent Events

    • 22 Feb 2018 Planned End Date changed from 1 Mar 2019 to 29 Mar 2019.
    • 22 Feb 2018 Planned primary completion date changed from 1 Mar 2019 to 29 Mar 2019.
    • 17 Jan 2018 Planned End Date changed from 12 Mar 2019 to 1 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top